Sarepta Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has requested that the company provide dystrophin data from biopsies that were taken as part of the ongoing confirmatory study of eteplirsen, called PROMOVI. The data was requested by the agency in connection with its ongoing evaluation of Sarepta’s New Drug Application (NDA) . . .
Individuals with central core disease (CCD), centronuclear myopathy (CNM), multiminicore myopathy (MMC) or other diseases caused by a mutation in the ryanodine receptor (RYR-1) are invited to attend the first-ever RYR-1 International Family Conference, organized by the RYR-1 Foundation, July 22-24, 2016, in Baltimore. At the conference, you will be able to view presentations by . . .
MDA Amplify is a new mobile app that revolutionizes the way you — an MDA supporter, partner or family — can share MDA news on your own social media channels. To become an MDA Amplifier, download the MDA Amplify app from iTunes or Google Play store (it’s free!), connect your personal social media accounts, and . . .
Although I would later come to associate MDA Summer Camp with the words joy, freedom and independence, that’s not how I felt in the beginning. In fact, I was terrified to go. When my mom told me she had signed me up for MDA’s summer camp in Empire, Colorado, I threw a massive temper tantrum . . .
Michelle Murphy is an avid runner. She routinely pounds the pavement through the neighborhoods of Albany, NY. When she needs a change of pace, she runs on the path through the park that skirts the Hudson River. Michelle even hoofs it to and from the gym. You’d never guess that the 24-year-old has Myotonic muscular . . .
BioMarin Pharmaceutical announced May 31 that it is discontinuing development of its exon skipping drug drisapersen. The company recently withdrew its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting that indicated the CHMP intended to issue a negative . . .
